Thrombolytic Drugs Discussion Paper

Thrombolytic Drugs Discussion Paper

Thrombolytic drugs are used to reduce the risk of heart attack due to blood clots. The clots prevent the smooth flow of the blood in the vessels and could result in ischemia. The commonly used thrombolytic therapy is the tissue plasminogen activator (Marko et al., 2020). The medication acts by breaking up the blood clots as well as cleaving the zymogen plasminogen at the Arg561-Val562 peptide bonds. The cleavage results in the formation of the serine protease, which is plasmin (Alawieh et al., 2018). The common side effects of the medication include headache, increased menstrual flow, and excess bleeding at the puncture sites. The medication interacts with warfarin, aspirin, and nonsteroidal anti-inflammatory drugs such as ibuprofen. Therefore, the medication should not be used on patients already using warfarin because the INR will increase too much.


The healthcare providers ought to assess the patient’s health conditions and history to determine the best treatment options to address their health issues. Genetic and cultural factors influence the efficacy of the medication administered to the patient. Poor adherence to the medication results in lower efficacy and poor treatment outcomes for the patient. Patients must be educated on the need to adhere to the prescription until otherwise revised. Also, the patients should not take more than one medication without consulting their healthcare providers. Some patients have the customs of seeking treatment from more than one healthcare provider and so they end up being subjected to polypharmacy. In terms of genetic factors, the level of immunogenicity tends to vary with the genes an individual has. Some patients react adversely to some medications because of their genetic composition (Shi et al., 2021). The healthcare providers should seek to determine whether the patient has any history of adverse drug reactions and exclude them from the prescription.


Alawieh, A., Andersen, M., Adkins, D. L., & Tomlinson, S. (2018). Acute complement inhibition potentiates Neurorehabilitation and enhances tpa-mediated Neuroprotection. The Journal of Neuroscience38(29), 6527-6545.

Marko, M., Posekany, A., Szabo, S., Scharer, S., Kiechl, S., Knoflach, M., Serles, W., Ferrari, J., Lang, W., Sommer, P., & Greisenegger, S. (2020). Trends of R-tpa (Recombinant tissue-type plasminogen activator) treatment and treatment-influencing factors in acute ischemic stroke. Stroke51(4), 1240-1247.

Struggling to meet your deadline ?

Get assistance on

Thrombolytic Drugs Discussion Paper

done on time by medical experts. Don’t wait – ORDER NOW!

Shi, K., Zou, M., Jia, D., Shi, S., Yang, X., Liu, Q., Dong, J., Sheth, K. N., Wang, X., & Shi, F. (2021). TPA mobilizes immune cells that exacerbate hemorrhagic transformation in stroke. Circulation Research128(1), 62-75.


please answer discussion question below minimum 250 words,

Choose a thrombolytic drug and provide an appropriate indication for use. Share the mechanism of action of this medication and hints for monitoring, including absolute contraindications and relative contraindications, as well as side effects and drug interactions, including interactions with CAM. What ethnic, cultural, and genetic differences need to be considered when prescribing these medications? Include the name of the medication in the subject line so that the medications can be followed. Include references using APA format.

Open chat
WhatsApp chat +1 908-954-5454
We are online
Our papers are plagiarism-free, and our service is private and confidential. Do you need any writing help?